Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day. The product is a generic version of Climara Pro® Transdermal System. The USFDA has designated the product under its Competitive Generic Therapy (CGT) pathway. Zydus is eligible for a 180-day exclusivity period available to certain first-approved applicants under this pathway, subject to the provisions of the US Federal Food, Drug, and Cosmetic Act. Any applicable exclusivity period will begin when the product is first commercially marketed.
Estradiol and Levonorgestrel Transdermal System is used to treat moderate to severe symptoms of menopause. It is also indicated for the prevention of osteoporosis in postmenopausal women. The product will be manufactured at Zydus Group’s facility in Moraiya, near Ahmedabad, Gujarat. The approval expands the company’s portfolio of products approved for the US market and adds to its presence in the women’s healthcare segment.
According to IQVIA data for the 12 months ended August 2026, the product recorded annual sales of approximately US$45.7 million in the United States. The market size provides an indication of the commercial opportunity available for the approved generic product.
The latest approval takes the Zydus Group’s total number of USFDA approvals to 458. The company has filed 516 abbreviated new drug applications with the US regulator to date. The CGT pathway was introduced to encourage the development and approval of generic medicines where competition may be limited. The 180-day exclusivity provision is subject to regulatory conditions and does not automatically begin on the date of approval; it is linked to the first commercial marketing of the product, where applicable.
The approval marks another addition to Zydus Lifesciences’ US generics portfolio. The company continues to develop and file generic medicines for regulated markets, supported by its manufacturing and research capabilities in India. Zydus Lifesciences Limited is an Indian pharmaceutical company with operations spanning the development, manufacture and marketing of medicines and healthcare products. The company serves domestic and international markets and has a portfolio covering multiple therapeutic areas. Its operations include research and development, manufacturing and regulatory submissions for pharmaceutical products across global markets.
